# EDGAR Filing Document

**Accession Number:** 0001894525
**File Stem:** 0001213900-25-112184
**Filing Date:** 2025-11
**Character Count:** 8052
**Document Hash:** d9c9ac66ae2871d29f7c7a5e10abbfcb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-112184.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001213900-25-112184

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251113

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apimeds Pharmaceuticals US, Inc.
- **CENTRAL INDEX KEY:** 0001894525
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851099700
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42545
- **FILM NUMBER:** 251495596

**BUSINESS ADDRESS:**
- **STREET 1:** 100 MATAWAN RD
- **STREET 2:** SUITE 325
- **CITY:** MATAWAN
- **STATE:** NJ
- **ZIP:** 07747
- **BUSINESS PHONE:** 848-201-5010

**MAIL ADDRESS:**
- **STREET 1:** 100 MATAWAN RD
- **STREET 2:** SUITE 325
- **CITY:** MATAWAN
- **STATE:** NJ
- **ZIP:** 07747

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **November 13, 2025**

**Apimeds Pharmaceuticals US, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42545** | **85-1099700** |
| (State or other jurisdiction <br> of incorporation) | (Commission File Number) | (I.R.S. Employer <br> Identification Number) |

---

---

| | |
|:---|:---|
| **100 Matawan Rd, Suite 325**<br> **Matawan, New Jersey** | **07747** |
| (Address of principal executive offices) | (Zip code) |

---

Registrant's telephone number, including area code: **(848) 201-5010**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | APUS | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 13, 2025 (the "Effective Date"), Apimeds Pharmaceuticals US, Inc. (the "Company") entered into an amendment (the "Amendment") to the Executive Employment Agreement, dated September 21, 2023 (the "Agreement"), with Erik Emerson, the Company's Chief Executive Officer (the "Executive"). Effective as of the Effective Date, the Amendment increases the Executive's annual base salary to $500,000. It also provides that, if the Executive is terminated by the Company without cause, the Executive will be entitled to a severance payment equal to twenty-four (24) months of base salary and benefits and immediate vesting of all unvested equity, subject to the Executive's execution of a release of claims against the Company. The amendment further clarifies that, upon termination by the Company for cause or by the Executive without good reason, any unvested equity will be automatically forfeited without payment or consideration by the Company.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Amendment to Executive Employment Agreement, dated November 13, 2025](ea026616601ex10-1_apimeds.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Apimeds Pharmaceuticals US, Inc. | Apimeds Pharmaceuticals US, Inc. |
| Date: November 18, 2025 | By: | /s/ Erik Emerson |
|  | Name: | Erik Emerson |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>AMENDMENT TO EXECUTVIE EMPLOYMENT AGREEMENT</u>**

**<u> </u>**

**This EXECUTIVE EMPLOYMENT AGREEMENT** hereby amends the Executive Employment Agreement, dated as of September 21, 2023 entered into by and between Apimeds Pharmaceutical US, Inc., a Delaware corporation having its principal place of business at 25 Edinburg Circle, Matawan, NJ 07747 (the "<u>Company</u>"), and Erik Emerson an individual residing for the purposes set forth in this agreement in the State of New Jersey ("<u>Executive</u>") is hereby amended as follows effective November 13, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;1. Effective November 13, 2025, Executive's yearly salary shall be $500,000.

&nbsp;&nbsp;&nbsp;&nbsp;2. Effective November 13, 2025, Paragraph 3(c) of the September 21, 2023 Agreement is amended to read: "Executive's
employment may be terminated without Cause upon thirty (30) days' written notice to Executive. Upon termination without cause, Executive
shall be entitled to receive a severance payment equal to twenty-four (24) months of Executive's salary and benefits, in exchange
for signing a release of claims against the Company. In the event that Executive is terminated without cause, all equity will vest on
the date of termination."

&nbsp;&nbsp;&nbsp;&nbsp;3. Effective November 13, 2025, Paragraph 3(e) of the September 21, 2023 Agreement is amended to read: "Upon
Executive's death or Disability, the termination of Executive's employment by the Company for Cause, or the termination of
Executive's termination of his employment with the Company without Good Reason, the Unvested Portion of restricted stock awarded
pursuant to this Agreement shall be automatically forfeited to the Company and all of the Executive's rights to such shares shall
immediately terminate without any payment or consideration by the Company. Upon Executives termination of his employment by the Company
without cause, any unvested shares shall vest on the date of termination."

---

| | | |
|:---|:---|:---|
| <u>COMPANY</u>: | <u>COMPANY</u>: | <u>EXECUTIVE</u>: |
| Apimeds Pharmaceutical US, Inc., | Apimeds Pharmaceutical US, Inc., |  |
| a New Jersey Corporation, | a New Jersey Corporation, |  |
| By: | /s/ Christopher Kim | /s/ Erik Emerson |
|  | Christopher Kim, Chairman | Erik Emerson, individually |

---